The guidelines now include Guardant's blood-based test Shield and Freenome's SimpleScreen, along with Geneoscopy's stool-based ColoSense assay and Abbott's Cologuard Plus assay.
The company, which received UKCA marking for the platform in February, also said it has secured a £2.1 million non-dilutive loan from Innovate UK.
The collaboration aims to expand access to patient samples, enhance clinical validation, and accelerate the development of multiomic diagnostics in women's health.
The test uses mass spectrometry combined with machine learning to detect patterns of urinary volatile organic compounds linked to Alzheimer's disease.
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
NEW YORK – US Congressman Neal Dunn, R-Fla. introduced a bill into the House of Representatives on Tuesday that would update the Clinical Laboratory Improvement Amendments (CLIA) to provide new ...
During a third phase of the pilot, set to begin in the third quarter of 2027, the EMA will open the program to IVD makers and notified bodies.
The assay delivers a risk score that can help clinicians to tailor treatment intensity to a patient's risk of disease progression.
NEW YORK — Cancer Check Labs said on Thursday that it has signed an agreement to offer its blood-based cancer screening test through Evexia Diagnostics' ordering platform. The test — called ...
The test is covered for recurrence monitoring following treatment with curative intent in individuals with muscle-invasive bladder cancer and will be available starting June 1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results